Crispr therapeutics ag (CRSP)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Dec'15
Assets
Current assets:
Cash and cash equivalents

889,712

943,771

629,717

427,885

437,549

456,600

487,295

319,737

341,767

239,758

253,519

272,264

288,872

315,520

228,613

155,961

Accounts receivable

25,117

99

39

321

331

88

552

944

1,260

2,626

3,211

6,814

5,672

3,157

2,092

339

Prepaid expenses and other current assets

14,453

43,677

34,309

10,267

11,916

9,658

8,841

9,868

8,451

6,001

1,856

2,207

1,918

1,511

946

540

Total current assets

929,282

987,547

664,065

438,473

449,796

466,395

496,688

330,549

351,478

248,385

258,586

281,285

296,462

320,188

231,651

156,840

Property and equipment, net

31,773

31,330

21,074

20,156

18,871

18,500

18,097

18,395

18,907

18,857

19,564

19,927

22,165

21,027

3,862

1,328

Intangible assets, net

221

235

249

262

276

289

303

317

331

344

358

372

385

399

413

454

Restricted cash

5,041

5,041

3,915

3,915

3,163

3,200

3,165

3,165

3,165

3,154

3,154

3,154

3,151

3,150

3,153

700

Operating lease assets

40,321

41,502

30,619

30,770

25,098

-

-

-

-

-

-

-

-

-

-

-

Equity method investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35,686

-

Other non-current assets

662

1,097

668

669

669

669

650

704

571

606

657

237

183

198

3,888

101

Total assets

1,007,300

1,066,752

720,590

494,245

497,873

489,016

518,903

353,130

374,452

271,346

282,319

304,975

322,346

344,962

278,653

159,423

Liabilities and shareholders’ equity
Current liabilities:
Accounts payable

11,277

5,944

3,374

7,143

7,131

5,069

5,221

4,479

2,546

1,639

2,116

2,559

3,937

4,569

1,943

1,584

Accrued expenses

21,924

30,180

22,397

18,628

15,680

20,852

25,835

12,702

10,227

11,361

8,485

11,888

11,699

16,320

12,402

8,430

Deferred revenue, current

803

960

47,725

-

-

102

-

-

-

-

-

-

-

-

-

-

Accrued tax liabilities

284

583

1,478

542

615

402

24

47

433

347

427

272

190

23

82

81

Deferred rent

-

-

-

-

-

1,202

1,027

1,027

1,027

1,027

1,027

1,027

1,027

1,027

-

-

Operating lease liabilities

9,005

8,489

4,805

4,880

4,899

-

-

-

-

-

-

-

-

-

-

-

Deferred gain

-

-

-

-

-

-

-

-

-

-

-

-

-

-

63,608

-

Other current liabilities

11,793

10,950

-

219

73

119

171

226

162

137

62

68

62

59

62

60

Total current liabilities

55,086

57,106

79,779

31,412

28,398

27,746

32,278

18,481

14,395

14,511

12,117

15,814

16,915

21,998

78,097

10,155

Deferred revenue, non-current

11,776

11,776

11,871

57,730

57,755

57,780

57,806

57,832

57,858

56,928

79,689

79,232

78,311

77,646

76,949

75,090

Convertible loan, including accrued interest of $0 and $97 as of December 31, 2016 and 2015, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38,336

Deferred rent non-current

-

-

-

-

-

11,052

11,232

11,380

11,566

11,761

11,380

11,928

11,768

12,283

-

164

Operating lease liabilities, net of current portion

42,390

44,050

36,827

37,200

31,728

-

-

-

-

-

-

-

-

-

-

-

Other non-current liabilities

11,951

14,395

235

220

182

243

273

283

298

314

175

198

177

189

574

281

Total liabilities

121,203

127,327

128,712

126,562

118,063

96,821

101,589

87,976

84,117

83,514

103,361

107,172

107,171

112,116

155,620

124,026

Commitments and contingencies, see Note 4

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

Shareholders’ equity:
Common shares, CHF 0.03 par value, 103,901,006 and 103,901,006 shares authorized at March 31, 2020 and December 31, 2019, respectively, 61,122,431 and 61,034,025 shares issued at March 31, 2020 and December 31, 2019, respectively 60,890,035 and 60,783,799 shares outstanding at March 31, 2020 and December 31, 2019, respectively.

1,850

1,847

1,684

1,630

1,589

1,584

1,575

1,435

1,423

1,240

1,234

1,226

1,216

1,216

174

181

Treasury shares, at cost, 232,396 and 250,226 shares at March 31, 2020 and December 31, 2019, respectively.

63

63

57

57

57

57

57

50

0

0

0

0

0

0

0

0

Additional paid-in capital

1,178,770

1,162,345

845,526

759,796

718,255

682,245

659,776

457,032

443,774

312,018

303,292

297,446

292,519

288,739

11,553

4,636

Accumulated deficit

-294,442

-224,711

-255,253

-393,676

-339,977

-291,569

-243,979

-193,268

-154,888

-125,440

-125,580

-100,873

-78,558

-57,083

-74,182

-33,906

Accumulated other comprehensive (loss) income

-18

7

-22

-10

-

-8

-1

5

26

14

12

4

-2

-26

-26

-8

Total shareholders' equity

886,097

939,425

591,878

367,683

379,810

392,195

417,314

265,154

290,335

187,832

178,958

197,803

215,175

232,846

-62,481

-29,097

Noncontrolling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-51

-27

Total shareholders equity (deficit)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-62,532

-29,124

Total liabilities and shareholders’ equity

1,007,300

1,066,752

720,590

494,245

497,873

489,016

518,903

353,130

374,452

271,346

282,319

304,975

322,346

344,962

278,653

159,423